210 related articles for article (PubMed ID: 37817092)
1. Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials.
Fu Z; Gao C; Xie J; Zhang C; Li S; Gu M; Shi C
BMC Cancer; 2023 Oct; 23(1):960. PubMed ID: 37817092
[TBL] [Abstract][Full Text] [Related]
2. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis.
Fu Z; Liu J; Li S; Shi C; Zhang Y
EClinicalMedicine; 2023 Jan; 55():101795. PubMed ID: 36712893
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
Zhu Y; Liu K; Wang K; Zhu H
Cancer; 2023 Jan; 129(2):283-295. PubMed ID: 36408673
[TBL] [Abstract][Full Text] [Related]
5. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
[TBL] [Abstract][Full Text] [Related]
6. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis.
Zhu Z; Shen G; Li J; Qiu T; Fang Q; Zheng Y; Xin Y; Liu Z; Zhao F; Ren D; Zhao J
Crit Rev Oncol Hematol; 2023 Apr; 184():103960. PubMed ID: 36907365
[TBL] [Abstract][Full Text] [Related]
7. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database.
Ma Z; Zhang Y; Zhu M; Feng L; Zhang Y; An Z
Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1351-1361. PubMed ID: 36111954
[TBL] [Abstract][Full Text] [Related]
9. Incidence of HER2-targeted antibody-drug conjugates-related cardiac events: a meta-analysis.
Liu F; Li H; Yin G; Pan Y
J Cancer; 2024; 15(1):90-102. PubMed ID: 38164284
[No Abstract] [Full Text] [Related]
10. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.
Tarantino P; Modi S; Tolaney SM; Cortés J; Hamilton EP; Kim SB; Toi M; Andrè F; Curigliano G
JAMA Oncol; 2021 Dec; 7(12):1873-1881. PubMed ID: 34647966
[TBL] [Abstract][Full Text] [Related]
11. Incidence of antibody-drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis.
Zhang H; Shen G; Yang P; Li J; Li Z; Liu Z; Wang M; Zhao F; Ren D; Liu Z; Zhao J; Zhao Y
Crit Rev Oncol Hematol; 2024 Apr; 196():104292. PubMed ID: 38403093
[TBL] [Abstract][Full Text] [Related]
12. Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials.
Zhang Y; Ma Z; Sun X; Feng X; An Z
Breast; 2022 Apr; 62():162-169. PubMed ID: 35219113
[TBL] [Abstract][Full Text] [Related]
13. Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody-drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore.
Yong WP; Teo FS; Teo LL; Ng MC; Tan TJ; Low SY; Wong K; Ang P; Choo SP; Lee KH; Lee SC
Expert Opin Drug Metab Toxicol; 2022 Dec; 18(12):805-815. PubMed ID: 36636012
[TBL] [Abstract][Full Text] [Related]
14. Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment.
Ji C; Li F; Yuan Y; Zhang H; Bian L; Zhang S; Wang T; Li J; Jiang Z
Oncologist; 2023 Oct; 28(10):e859-e866. PubMed ID: 37218076
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
16. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
17. Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis.
Zhang L; Shen D; Yu L; Yan Y; Wasan HS; Yu J; Zhang S; Sun L
Crit Rev Oncol Hematol; 2022 Sep; 177():103758. PubMed ID: 35868498
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy with
Zhu J; Min N; Chen Y; Li X
Ann Transl Med; 2023 Mar; 11(5):200. PubMed ID: 37007556
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
[TBL] [Abstract][Full Text] [Related]
20. The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review.
Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Crit Rev Oncol Hematol; 2023 Dec; 192():104189. PubMed ID: 37866413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]